Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The TRACK trial is an investigator-initiated, multicentre, prospective, randomised,
double-blind, placebo-controlled trial. TRACK is a global trial and will be conducted in
renal units that provide comprehensive CKD care. Approximately 2000 participants will be
recruited.
The TRACK trial will assess a strategy of administering low dose rivaroxaban to reduce the
risk of major adverse cardiac event (MACE) in people with Chronic Kidney Disease (CKD) stages
4 or 5 or dialysis-dependent End Stage Kidney Disease (ESKD), and elevated cardiovascular
(CV) risk, whilst maintaining an acceptable bleeding risk.